SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 236.15

Change

0.00 (0.00)%

Market Cap

USD 0.70B

Volume

44.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.20 (+0.74%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.40 (+0.79%)

USD 117.56B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.43 (+0.78%)

USD 95.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.36 (-0.07%)

USD 89.53B
EUNL:F iShares Core MSCI World UCITS ..

N/A

USD 72.04B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.15 (+0.66%)

USD 71.25B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.95 (+0.41%)

USD 56.96B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 56.02B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.07 (+0.07%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.08 (+0.09%)

USD 51.63B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.81% 88% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.81% 85% B 71% C-
Trailing 12 Months  
Capital Gain 20.04% 75% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.04% 72% C 64% D
Trailing 5 Years  
Capital Gain 69.82% 83% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.82% 83% B 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.21% 73% C 69% C-
Dividend Return 8.21% 71% C- 63% D
Total Return N/A 61% D- 92% A
Risk Return Profile  
Volatility (Standard Deviation) 8.15% 70% C- 89% A-
Risk Adjusted Return 100.83% 98% N/A 97% N/A
Market Capitalization 0.70B 67% D+ 54% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike